Tsybruk Tatsiana V, Kaluzhskiy Leonid A, Mezentsev Yuri V, Makarieva Tatyana N, Tabakmaher Kseniya M, Ivanchina Natalia V, Dmitrenok Pavel S, Baranovsky Alexander V, Gilep Andrei A, Ivanov Alexis S
Institute of Bioorganic Chemistry NASB, 5 Building 2, V.F. Kuprevich Street, 220084 Minsk, Belarus.
Institute of Biomedical Chemistry, Pogodinskaya Str. 10 Building 8, 119121 Moscow, Russia.
Biomedicines. 2023 Oct 24;11(11):2873. doi: 10.3390/biomedicines11112873.
Due to the increasing prevalence of fungal diseases caused by fungi of the genus and the development of pathogen resistance to available drugs, the need to find new effective antifungal agents has increased. Azole antifungals, which are inhibitors of sterol-14α-demethylase or CYP51, have been widely used in the treatment of fungal infections over the past two decades. Of special interest is the study of CYP51, since this fungus exhibit resistance not only to azoles, but also to other antifungal drugs and there is no available information about the ligand-binding properties of CYP51 of this pathogen. We expressed recombinant CYP51 in cells and obtained a highly purified protein. Application of the method of spectrophotometric titration allowed us to study the interaction of CYP51 with various ligands. In the present work, the interaction of CYP51 with azole inhibitors, and natural and synthesized steroid derivatives was evaluated. The obtained data indicate that the resistance of to azoles is not due to the structural features of CYP51 of this microorganism, but rather to another mechanism. Promising ligands that demonstrated sufficiently strong binding in the micromolar range to CYP51 were identified, including compounds 99 (Kd = 1.02 ± 0.14 µM) and Ch-4 (Kd = 6.95 ± 0.80 µM). The revealed structural features of the interaction of ligands with the active site of CYP51 can be taken into account in the further development of new selective modulators of the activity of this enzyme.
由于由该属真菌引起的真菌疾病患病率不断上升,且病原体对现有药物产生耐药性,寻找新型有效抗真菌药物的需求日益增加。唑类抗真菌药是甾醇-14α-脱甲基酶或CYP51的抑制剂,在过去二十年中已广泛用于治疗真菌感染。特别值得关注的是对该CYP51的研究,因为这种真菌不仅对唑类耐药,还对其他抗真菌药物耐药,且关于该病原体CYP51的配体结合特性尚无可用信息。我们在细胞中表达了重组CYP51,并获得了高度纯化的蛋白。应用分光光度滴定法使我们能够研究该CYP51与各种配体的相互作用。在本研究中,评估了该CYP51与唑类抑制剂、天然和合成甾体衍生物的相互作用。所得数据表明,该菌对唑类的耐药性并非由于该微生物CYP51的结构特征,而是另有机制。确定了在微摩尔范围内对该CYP51表现出足够强结合力的有前景的配体,包括化合物99(Kd = 1.02 ± 0.14 μM)和Ch-4(Kd = 6.95 ± 0.80 μM)。在该酶活性的新型选择性调节剂的进一步开发中,可以考虑所揭示的配体与该CYP51活性位点相互作用的结构特征。